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The majority of the 3 million HIV-infected individuals
currently believed to be on antiretroviral therapy (ART)
are predominantly from the developing world. Most are
on firstline therapy with no prior experience of ART. Inev-
itably antiretroviral failure will occur in some requiring
switch to secondline ART. In a WHO survey of 23
resource-limited countries in early 2006, 96% of adult
patients were on first line ART and only 4% (1% to 15%)
were on secondline ART. In children, the corresponding
figures were 99% and 1%. There was great variability in
what was considered secondline ART by respondents.
Resource availability is central to the roll out of ART in the
developing world. While drug availability and human
resource concerns are being actively addressed through a
variety of initiatives, the availability and distribution of
laboratory facilities are likely to remain an impediment to
the diagnosis and management of ART failure. Discussion
of ART failure in the developing world has centred on cri-
teria for clinical, immunological and virologic failure.
Conceptually virologic failure is regarded as early diagno-
sis whilst clinical failure as late diagnosis of failure. Cen-
tral to the occurrence of ART failure is the resumption of
viral replication which clearly requires demonstration of
the return of viraemia by viral load measurement. Moreo-
ver, to optimally guide the choice of secondline drugs,
resistance testing is essential. With resource limitations,
clinical and occasionally immunological assessment is the
only option available to diagnose ART failure in most
parts of the developing world. This inevitably results in
patients being switched to secondline therapy after they
have accumulated a large number of resistance mutations
as exemplified in several studies such as the DART study
in Zimbabwe and Uganda and studies in Malawi, India
and elsewhere. Conversely, reliance on clinical and
immumological criteria for the diagnosis of ART failure
may result in patients who have not failed being switched
to secondline ART. Secondline ART strategies in the devel-
oping world must of necessity take into account resource
constraints. Viral load determination and realtime resist-
ance testing will not become a reality for the majority of
patients presumed to fail firstline ART in this environ-
ment. The best strategies to identify and manage firstline
ART failure and the best ways to choose secondline ART
combinations in the developing world are inevitably prag-
matic and often based on expert opinion rather that hard
evidence.
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